4. GlaukosR&D spending: $49,676,000
Percentage of revenues: 27.4%
2019 overall revenue ranking: 87
Glaukos’s research and development expenses went toward new product development projects, pre-clinical studies, IDE studies and other clinical trials.
The company said in its SEC annual report filing that it plans to expand pharmaceutical and IOP sensor development efforts, as well as clinical trials.
Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at dkirsh@wtwhmedia.com.
